Compare BridgeBio Pharma Inc (BBIO) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.6. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | EMLC | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Fixed Income |
52-Week High | $90.17 | $26.59 |
52-Week Low | $47.29 | $24.83 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
EMLC trades at $25.72, up 0.67% today, with a bullish technical signal driven by moving averages. Recent dividends include $0.14 paid in June 2026. The stock shows strong momentum indicators, though RSI levels suggest potential overbought conditions near-term.
Outlook remains positive given technical strength and dividend yield, but limited fundamental data availability warrants caution. Risks include emerging market volatility and Fed policy sensitivity. Analyst sentiment leans bullish, but investors should seek updated financial disclosures for full assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
